selected scholarly activity
-
conferences
- Clinical Correlates of Predictors of Hypoglycemia over Four Years in 2,729 People with Type 2 Diabetes Starting Insulin. Diabetes. A107-A107. 2017
- SERUM GAMMA-GLUTAMYL-TRANSFERASE TRANSPEPTIDASE (GGT) AS A PREDICTOR OF CHOLEDOCHOLITHIASIS. Gastroenterology. A529-A529. 1988
-
journal articles
- International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thrombosis Journal. 17:7. 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 394:121-130. 2019
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. 394:131-138. 2019
- Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 8:e010510. 2019
- Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurology. 17:1053-1060. 2018
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. The Lancet. 392:2269-2279. 2018
- Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 70:828-835. 2018
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 392:1519-1529. 2018
- Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. International Journal of Stroke. 13:420-443. 2018
- Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, Obesity and Metabolism. 20:921-929. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists. British Journal of Haematology. 174:610-623. 2016
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 39:709-716. 2016
- Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association. 5:e002197-e002197. 2016
- Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Canadian Journal of Psychiatry. 60:189-199. 2015
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation. Cardiovascular Quality and Outcomes. 8:S12-S20. 2015
- Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. Data from the international CLARIFY registry. European Heart Journal. 34:P530-P530. 2013
- n–3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia. New England Journal of Medicine. 367:1760-1761. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal. 155:26.e1-26.e13. 2008